Jian Xie Biography and Net Worth



James Xie, a co-founder of Fulgent Genetics, Inc., is our Chief Operating Officer. Prior to joining Fulgent, Mr. Xie served as the Senior Vice President of Cogent Inc., a publicly traded biometric identification service and product company from 1996 until 2011. As Chief Operating Officer of Fulgent, Mr. Xie is responsible for managing all global operations, product vision and product engineering. He is focused on unifying all departments to maximize efficiency, drive sustainable growth and inspire continuous innovation.

He received his B.A. in Engineering from Chongqing University in 1987, and has both an M.S. in Industrial Engineering and an M.S. in Computer Science from the University of New South Wales in 1992.  

In his free time, he also is a flight instructor for single-engine, multi-engine, and instrument airplanes. He holds a Commercial Pilot’s License (CPL) and Airline Transport Pilot’s License (ATPL).

What is Jian Xie's net worth?

The estimated net worth of Jian Xie is at least $7.30 million as of December 11th, 2023. Mr. Xie owns 363,124 shares of Fulgent Genetics stock worth more than $7,302,424 as of April 19th. This net worth approximation does not reflect any other assets that Mr. Xie may own. Additionally, Mr. Xie receives an annual salary of $755,730.00 as COO at Fulgent Genetics. Learn More about Jian Xie's net worth.

How old is Jian Xie?

Mr. Xie is currently 58 years old. There are 4 older executives and no younger executives at Fulgent Genetics. The oldest executive at Fulgent Genetics is Mr. Ming Hsieh, Chairman & CEO, who is 68 years old. Learn More on Jian Xie's age.

What is Jian Xie's salary?

As the COO of Fulgent Genetics, Inc., Mr. Xie earns $755,730.00 per year. There are 2 executives that earn more than Mr. Xie. The highest earning executive at Fulgent Genetics is Mr. Ming Hsieh, Chairman & CEO, who commands a salary of $1,660,000.00 per year. Learn More on Jian Xie's salary.

How do I contact Jian Xie?

The corporate mailing address for Mr. Xie and other Fulgent Genetics executives is 4978 SANTA ANITA AVENUE, TEMPLE CITY CA, 91780. Fulgent Genetics can also be reached via phone at (626) 350-0537 and via email at [email protected]. Learn More on Jian Xie's contact information.

Has Jian Xie been buying or selling shares of Fulgent Genetics?

Jian Xie has not been actively trading shares of Fulgent Genetics during the last quarter. Most recently, Jian Xie sold 22,000 shares of the business's stock in a transaction on Monday, December 11th. The shares were sold at an average price of $26.52, for a transaction totalling $583,440.00. Following the completion of the sale, the chief operating officer now directly owns 363,124 shares of the company's stock, valued at $9,630,048.48. Learn More on Jian Xie's trading history.

Who are Fulgent Genetics' active insiders?

Fulgent Genetics' insider roster includes John Bolger (Director), Hanlin Gao (Insider), Ming Hsieh (Chairman & CEO ), Paul Kim (CFO), and Jian Xie (COO). Learn More on Fulgent Genetics' active insiders.

Are insiders buying or selling shares of Fulgent Genetics?

During the last twelve months, insiders at the sold shares 14 times. They sold a total of 48,255 shares worth more than $1,448,973.19. The most recent insider tranaction occured on December, 11th when COO Jian Xie sold 22,000 shares worth more than $583,440.00. Insiders at Fulgent Genetics own 31.8% of the company. Learn More about insider trades at Fulgent Genetics.

Information on this page was last updated on 12/11/2023.

Jian Xie Insider Trading History at Fulgent Genetics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/11/2023Sell22,000$26.52$583,440.00363,124View SEC Filing Icon  
12/4/2023Sell1,779$27.57$49,047.03385,124View SEC Filing Icon  
11/16/2023Sell1,617$27.25$44,063.25386,903View SEC Filing Icon  
9/7/2023Sell1,492$31.41$46,863.72416,022View SEC Filing Icon  
8/17/2023Sell1,307$33.88$44,281.16417,514View SEC Filing Icon  
6/2/2023Sell1,433$40.30$57,749.90425,794View SEC Filing Icon  
11/30/2022Sell685$34.39$23,557.15430,074View SEC Filing Icon  
8/30/2022Sell675$44.18$29,821.50309,729View SEC Filing Icon  
5/16/2022Sell1,269$53.38$67,739.22329,701View SEC Filing Icon  
11/29/2021Sell636$95.42$60,687.12View SEC Filing Icon  
8/30/2021Sell622$91.25$56,757.50311,195View SEC Filing Icon  
8/16/2021Sell1,223$95.12$116,331.76View SEC Filing Icon  
5/28/2021Sell647$73.46$47,528.62337,394View SEC Filing Icon  
5/25/2021Sell2,000$72.21$144,420.00338,041View SEC Filing Icon  
5/20/2021Sell1,000$74.48$74,480.00341,041View SEC Filing Icon  
5/18/2021Sell931$70.71$65,831.01341,041View SEC Filing Icon  
3/9/2021Sell62,000$102.65$6,364,300.00345,476View SEC Filing Icon  
12/2/2020Sell1,000$46.00$46,000.00434,085View SEC Filing Icon  
11/30/2020Sell3,396$43.22$146,775.12434,085View SEC Filing Icon  
11/17/2020Sell3,706$45.34$168,030.04447,585View SEC Filing Icon  
8/28/2020Sell441$30.82$13,591.62601,295View SEC Filing Icon  
8/3/2020Sell1,976$27.86$55,051.36603,712View SEC Filing Icon  
See Full Table

Jian Xie Buying and Selling Activity at Fulgent Genetics

This chart shows Jian Xie's buying and selling at Fulgent Genetics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Fulgent Genetics Company Overview

Fulgent Genetics logo
Fulgent Genetics, Inc., together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company's clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases. Its therapeutic development solutions focus on developing drug candidates for treating a range of cancers using a nanoencapsulation and targeted therapy platform to enhance the therapeutic window and pharmacokinetic profile of new and existing cancer drugs. The company operates picture genetics platform, which includes gene probes, data suppression and comparison algorithms, adaptive learning software, and proprietary laboratory information management systems that helps customers to identify health markers in their personal DNA. It serves insurance, hospitals, medical institutions, other laboratories, governmental bodies, payors, municipalities and large corporations, and patients. The company was formerly known as Fulgent Diagnostics, Inc. and changed its name to Fulgent Genetics, Inc. in August 2016. Fulgent Genetics, Inc. was founded in 2011 and is headquartered in El Monte, California.
Read More

Today's Range

Now: $20.11
Low: $19.90
High: $20.46

50 Day Range

MA: $22.76
Low: $20.09
High: $26.17

2 Week Range

Now: $20.11
Low: $19.88
High: $44.09

Volume

219,570 shs

Average Volume

202,980 shs

Market Capitalization

$601.29 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.43